Reaction product of phthalogen-brilliantblue IF3G with phenylguanazole and iron(II)-chloride

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

weight of evidence

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

data from handbook or collection of data

Remarks:

peer-reviewed OECD SIDS report

Cross-reference

Reason / purpose for cross-reference:

read-across source

Remarks:

link to target

Reference

Endpoint:

acute toxicity: oral

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

weight of evidence

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

data from handbook or collection of data

Remarks:

peer-reviewed OECD SIDS report, read-across substance

Justification for type of information:

REPORTING FORMAT FOR THE ANALOGUE APPROACH
1. HYPOTHESIS FOR THE ANALOGUE APPROACH
The ideal structure of the registered substance is a complex which consists of iron2+ as central ions and a hemiprophyrazine ring as ligand. Therefore, the endpoint in question may be both covered with data on Fe2+ salts as well as hemiprophyrazines and structurally related substances. So the read-across can be performed on both common functional groups and common breakdown products, as the read-across substances are considered breakdown products of the target substance.

2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
Source Chemicals, for individual read-across from an analogue in the required endpoints:
- Iron dichloride, CAS 7758-94-3
- Copper, (29H,31H-phthalocyaninato(2-)-kappaN29,kappaN30,kappaN31,kappaN32)-, ((3-(dimethylamino)propyl)amino)sulfonyl derivs., CAS 68411-04-1
- Copper phthalocyanine, CAS 147-14-8
Target Chemical:
(8,20-Dihydro-8,20-diphenyl-5,24:12,17-diimino-7,10:22,19-dinitrilodibenz(f,p)(1,2,4,9,11,12,14,19)
octaazacycloicosinato(2-)-N25,N26,N27,N28)iron, CAS 50293-39-5
All substances do not contain impurities to an extent which is expected to alter the outcome of the experimental results or read-across approach.

3. ANALOGUE APPROACH JUSTIFICATION
There are no data on the respective endpoints for all read-across substances available, but if data is available on all endpoints, a clear trend is available. So in general, read-across is justified. In detail, for the single possible structural analogues, the following is concluded:
CAS 7758-94-3: Both substances contain a Fe2+ ion, and with respect to acute oral toxicity, the substance provides the worst case scenario. So an underestimation of the actual risk here is unlikely. With regard to skin sensitization, iron does not need to be regarded, as it is an endogenous substance and no cases of sensitization were ever reported. Regarding gene mutation in bacteria, it was consistently with all the other possible analogues negative, so read-across is justified. For the irritation endpoints, it is not suitable, as based on the counterion, there are acidic iron salts available, clearly overestimating the possible hazard.
CAS 68411-04-1 / CAS 147-14-8: both source and target chemical contain structurally highly related chelating rings, i.e. a hemiprophyrazine ring or a phthalocyanine ring, they predominantly only differ in the central ion. The organic ring bearing all the chelating nitrogen atoms are identical, the only differ in the way the benzyl rings are attached, which are nevertheless identical chemical groups. With regard to acute oral toxicity, their acute oral LD50 values are way above the limit of classification, the precautionary classification of the target chemical as Acute tox. Cat. 4 does certainly not underestimate the actual risk. Regarding gene mutation in bacteria, all possible analogues are consistently negative ±S9. With regard to irritation and sensitisation, the organic functional groups are more relevant than the central ions, so read-across is also here justified.

4. DATA MATRIX
There is currently no data on the target chemical available, so an estimation using a worst case approach based on the properties of the available surrogates will be used:
Property CAS 50293-39-5 (target) CAS 7758-94-3 (source 1) CAS 68411-04-1 (source 2) CAS 147-14-8 (source 3)
LD50 (oral) Acute tox. Cat. 4 >300, <2000 mg/kg (rats) > 5000 mg/kg (rats) > 10000 mg/kg (rats)
>16000 mg/kg (rabbits)
Skin irritation Not irritating No data No data Not irritating
Eye irritation Not irritating No data No data Not irritating
Skin sensitization Not sensitizing No data No data Not sensitizing
Gene mutation in bacteria Negative ± S9 Negative ± S9 (OECD 471) Negative ± S9 (OECD 471) Negative ± S9 (various assays)

Reason / purpose for cross-reference:

read-across source

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Deviations:

not specified

GLP compliance:

yes

Test type:

acute toxic class method

Limit test:

no

Species:

rat

Strain:

Sprague-Dawley

Sex:

female

Details on test animals or test system and environmental conditions:

not available

Route of administration:

oral: unspecified

Vehicle:

not specified

Details on oral exposure:

Three Sprague-Dawley female rats were tested at each step and a starting dose of 300 mg/kg b.w. was selected. There was no mortality in the first three rats dosed with 300 mg/kg b.w. To confirm the starting dosage, three more rats were tested. In the second 300 mg/kg b.w. group, one animal was dead after one day. At the limit dosage of 2,000 mg/kg b.w., all three rats died after one hour of administration.

Doses:

300, 2000 mg/kg

No. of animals per sex per dose:

3

Control animals:

other: not required

Details on study design:

- Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight

Key result

Sex:

female

Dose descriptor:

LD50

Effect level:

> 300 - < 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: only range of LD50 value was given

Mortality:

There was no mortality in the first three rats dosed with 300 mg/kg b.w. To confirm the starting dosage, three more rats were tested. In the second 300 mg/kg b.w. group, one animal was dead after one day. At the limit dosage of 2,000 mg/kg b.w., all three rats died after one hour of administration.

Clinical signs:

other: There were no effects on body weight increase in all surviving animals. The typical clinical signs of tested animals at 2,000 mg/kg b.w. were nasal discharge, hypoactivity, piloerection, prone position, reddish change and edema on ears, fore-legs and hind

Gross pathology:

The necropsy of the tested animals at 2,000 mg/kg b.w. showed hemorrhage on lymphatic nodes, stomach, intestine and thymus. Also, there was hypertrophy of pancreas and spleen. In one dead animal of the 300 mg/kg b.w. group, hemorrhage on lymphatic nodes and intestine was observed.
There was no abnormality observed by microscopic examination of the surviving animals of the 300 mg/kg b.w. group after sacrifice on day 15.

Interpretation of results:

Category 4 based on GHS criteria

Conclusions:

Information was gathered from a peer-reviewed report / collection of data, hence, the information can be considered as sufficiently reliable to assess the acute oral toxicity of the test item. The LD50 value for acute oral toxicity of rats was between 300 and 2,000 mg/kg body weight, hence, it must be classified as acute toxic Cat. 4 acc. Regulation 1272/2008.

Executive summary:

In a toxicity test performed by OECD TG 423 (Acute Toxic Class Method) with GLP control, the LD50 value of the test item for acute oral toxicity of females Sprague-Dawley rats was between 300 and 2,000 mg/kg body weight.

Data source

Reference

Reference Type:

review article or handbook

Title:

Unnamed

Year:

2004

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Deviations:

not specified

GLP compliance:

yes

Test type:

acute toxic class method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Iron dichloride

EC Number:

231-843-4

EC Name:

Iron dichloride

Cas Number:

7758-94-3

IUPAC Name:

iron(2+) dichloride

Test material form:

solid

Remarks:

commercial product: liquid

Details on test material:

Water solubility : 650 g/L at 25 °C
Molecular Weight: 126.75
Synonyms:
Iron chloride (FeCl2)
Ferrous chloride
Ferrous chloride (FeCl2)
Ferrous dichloride
Iron protochloride
Iron(2+) chloride
Iron(II) chloride
Iron(II) chloride (FeCl2)
Iron(II) chloride (1:2)
Iron dichloride is in the form of white rhombohedral crystals and sometimes it has a green tint and the substance is very hygroscopic. Iron dichloride dihydrate (FeCl2•2H2O) is in the form of white monoclinic crystals with a pale green tint and loses 1 H2O at 120 °C. Also the substance is reported to lose 1 H2O at 150 – 160 °C. Iron dichloride tetrahydrate (FeCl2•4H2O) is in the form of pale green to blue-green monoclinic crystals or cryst powder and loses 2 H2O at 105 – 115 °C

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

female

Details on test animals or test system and environmental conditions:

not available

Administration / exposure

Route of administration:

oral: unspecified

Vehicle:

not specified

Details on oral exposure:

Three Sprague-Dawley female rats were tested at each step and a starting dose of 300 mg/kg b.w. was selected. There was no mortality in the first three rats dosed with 300 mg/kg b.w. To confirm the starting dosage, three more rats were tested. In the second 300 mg/kg b.w. group, one animal was dead after one day. At the limit dosage of 2,000 mg/kg b.w., all three rats died after one hour of administration.

Doses:

300, 2000 mg/kg

No. of animals per sex per dose:

3

Control animals:

other: not required

Details on study design:

- Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight

Results and discussion

Effect levels

Key result

Sex:

female

Dose descriptor:

LD50

Effect level:

> 300 - < 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: only range of LD50 value was given

Mortality:

There was no mortality in the first three rats dosed with 300 mg/kg b.w. To confirm the starting dosage, three more rats were tested. In the second 300 mg/kg b.w. group, one animal was dead after one day. At the limit dosage of 2,000 mg/kg b.w., all three rats died after one hour of administration.

Clinical signs:

other: There were no effects on body weight increase in all surviving animals. The typical clinical signs of tested animals at 2,000 mg/kg b.w. were nasal discharge, hypoactivity, piloerection, prone position, reddish change and edema on ears, fore-legs and hind

Gross pathology:

The necropsy of the tested animals at 2,000 mg/kg b.w. showed hemorrhage on lymphatic nodes, stomach, intestine and thymus. Also, there was hypertrophy of pancreas and spleen. In one dead animal of the 300 mg/kg b.w. group, hemorrhage on lymphatic nodes and intestine was observed.
There was no abnormality observed by microscopic examination of the surviving animals of the 300 mg/kg b.w. group after sacrifice on day 15.

Applicant's summary and conclusion

Interpretation of results:

Category 4 based on GHS criteria

Conclusions:

Information was gathered from a peer-reviewed report / collection of data, hence, the information can be considered as sufficiently reliable to assess the acute oral toxicity of the test item. The LD50 value for acute oral toxicity of rats was between 300 and 2,000 mg/kg body weight, hence, it must be classified as acute toxic Cat. 4 acc. Regulation 1272/2008.

Executive summary:

In a toxicity test performed by OECD TG 423 (Acute Toxic Class Method) with GLP control, the LD50 value of the test item for acute oral toxicity of females Sprague-Dawley rats was between 300 and 2,000 mg/kg body weight.